Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s – CNBC
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s CNBCExperimental Lilly combination drug tops Zepbound in weight-loss trial reuters.com‘Godzilla’ of weight-loss drugs could provide other important health benefits The GuardianBlockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs Scientific AmericanLilly’s Next-Gen Obesity Drug Helps People Lose Even More Weight in Study WSJ
সূত্র: মূল সংবাদসূত্র